Indium-111 capromab pendetide in the management of recurrent prostate cancer

Abstract

The provision of accurate prognostic information is a long-standing goal for effective management of prostate adenocarcinoma. Nontargeted imaging modalities are less efficient at detecting slow-growing prostate cancers. Prostate-specific membrane antigen has emerged as a superior biomarker, especially for the evaluation of metastatic spread. Advances in imaging technology have focused clinical interest on indium-111 capromab (¹¹¹In capromab) pendetide, a radioimmunoconjugate that detects prostate-specific membrane antigen expression in vivo. Single-photon emission computed tomography capromab pendetide images, fused with those generated by computed tomography or magnetic resonance, have engendered improvements in localization accuracy by correlating high signal intensity with anatomic structures. In long-term outcomes studies, fused ¹¹¹In capromab pendetide scans have delivered significant benefits for patient selection and improved treatment of prostate cancer.

Keywords::

• capromab pendetide
• ProstaScint^®
• prostate-specific membrane antigen
• radioimmunoscintigraphy

Financial & competing interests disclosure

Michael J Manyak is an employee of Cytogen Corporation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript. The author acknowledges the editorial assistance of Christopher J Jones, in the preparation of the manuscript.